Business
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Exosome Platform Technology-Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19--Novel Vaccine Induced Long-Lasting Immunity
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"Exosome Platform Technology-Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19--Novel Vaccine Induced Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins--Development of Safe, Non-toxic Exosome Formulation Capable of Delivering Functional mRNA in vitro and in vivo--Platform Expansion Underway Using Engineered Exosomes-\n Duchenne Muscular Dystrophy Program-In Discussions with FDA on Next Steps in Pathway Forward- CAP-1002 for COVID-19-Patient Screening Underway in Randomized, Double-Blind, Placebo-Controlled INSPIRE Study--To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today its financial results for the third quarter ending September 30, 2020 and provided a corporate update. “The Company’s development and achievements in the third quarter have been encouraging on multiple levels. We have continued to build momentum with our exosome platform technology as well as with our CAP-1002 program. The pandemic has provided a unique opportunity for the development of a vaccine candidate but also for the use of CAP-1002 as a potential therapeutic,” said Linda Marbán, Ph.D., Capricor’s president and chief executive officer. “We are advancing two separate and novel vaccine programs. Our strategy has evolved from our original plan to use exosomes from our cell as drug delivery vehicles to creating exosomes from multiple cell types that are readily available to build products that can be designed to address targets where delivery has proved to be challenging. We are now leveraging thought leaders and our own expertise to direct the development of exosome-based vaccines and exosome-based therapeutics. We expect significant pipeline expansion and will be seeking partnering opportunities in the months ahead to further cement our rebranding. I have never been more excited at the possibilities for Capricor,” Dr. Marbán added. The Company continues the development of our late-stage clinical asset, CAP-1002, for the treatment of advanced stages of DMD, and is currently in discussi...